These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Pescovitz MD Clin Transplant; 2006; 20(1):48-54. PubMed ID: 16556153 [TBL] [Abstract][Full Text] [Related]
30. Cardiac transplantation in the United States: an analysis of the UNOS registry. Everly MJ Clin Transpl; 2008; ():35-43. PubMed ID: 19708444 [TBL] [Abstract][Full Text] [Related]
31. The University of California at Los Angeles heart transplantation experience. Kobashigawa JA; Laks H; Wu G; Patel J; Moriguchi J; Hamilton M; Fonarow G; Fishbein M; Ardehali A Clin Transpl; 2005; ():173-85. PubMed ID: 17424734 [TBL] [Abstract][Full Text] [Related]
33. Heart transplantation across antibodies against human leukocyte antigen and ABO-post-transplant follow-up of donor reactive antibodies. Bućin D; Johansson S; Lindberg LO Xenotransplantation; 2006 Mar; 13(2):101-4. PubMed ID: 16623800 [TBL] [Abstract][Full Text] [Related]
34. Unique aspects of rejection and tolerance in liver transplantation. Knechtle SJ; Kwun J Semin Liver Dis; 2009 Feb; 29(1):91-101. PubMed ID: 19235662 [TBL] [Abstract][Full Text] [Related]
35. The University of Vienna experience in heart transplantation. Zuckermann A; Bohdjalian A; Deviatko E; Dunkler D; Rödler S; Ehrlich M; Wieselthaler G; Pacher R; Bunzel B; Wollenek G; Laczkovics A; Laufer G; Wolner E; Grimm M Clin Transpl; 2002; ():229-42. PubMed ID: 12971454 [TBL] [Abstract][Full Text] [Related]
36. The first year post-heart transplantation: use of immunosuppressive drugs and early complications. Sulemanjee NZ; Merla R; Lick SD; Aunon SM; Taylor M; Manson M; Czer LS; Schwarz ER J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):13-31. PubMed ID: 18287587 [TBL] [Abstract][Full Text] [Related]
38. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091 [TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499 [TBL] [Abstract][Full Text] [Related]
40. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? Higgins R; Kirklin JK; Brown RN; Rayburn BK; Wagoner L; Oren R; Miller L; Flattery M; Bourge RC; J Heart Lung Transplant; 2005 Apr; 24(4):392-400. PubMed ID: 15797738 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]